PMID- 24849690
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20221207
IS  - 2331-0936 (Electronic)
IS  - 0888-5109 (Linking)
VI  - 29
IP  - 5
DP  - 2014
TI  - A review of the efficacy and safety of canagliflozin in elderly patients with 
      type 2 diabetes.
PG  - 335-46
LID - 10.4140/TCP.n.2014.335 [doi]
AB  - OBJECTIVE: To review the efficacy and safety of canagliflozin (CAN) in elderly 
      patients with type 2 diabetes mellitus (T2DM). DATA SOURCES: Studies were 
      identified using PubMed, International Pharmaceutical Abstracts, MEDLINE, 
      Academic Search Premier, SCOPUS, and Google Scholar from 2011 to August 2013. The 
      following key words were reviewed: canagliflozin, canagliflozin elderly, 
      canagliflozin geriatrics, dapagliflozin, sodium glucose cotransporter 2 (SGLT2) 
      inhibitors, and SGLT2 receptor inhibitors. DATA EXTRACTION: Articles evaluating 
      CAN for diabetes that were published in English and used human subjects were 
      selected. Fifteen clinical trials were identified and evaluated. STUDY SELECTION: 
      Of 15 identified articles, 2 articles, 2 published posters, and unpublished 
      information from the manufacturer were chosen based on the mean age of the study 
      subjects. DATA SYNTHESIS: Evidence that elderly patients with T2DM have less A1C 
      reduction with CAN is presented; the benefit on A1C is significant. Systolic 
      blood pressure (SBP) and body weight reduction in the elderly were consistent 
      with younger patients. Adverse effects such as increased urinary frequency, 
      genital mycotic infections, and urinary tract infections may discourage the use 
      of CAN in the elderly patient. CONCLUSION: Treatment with CAN improves A1C 
      levels, reduces SBP and body weight, and is overall well tolerated in older 
      subjects with T2DM. Risks and benefits of treatment with CAN should be assessed 
      in geriatric patients on a case-by-case basis. Safety in elderly patients was 
      consistent with that of other phase 3 trials in the general population. 
      Additional longterm cardiovascular studies are needed.
FAU - Elmore, Lindsey K
AU  - Elmore LK
AD  - St. Vincent's Hospital, Birmingham, Alabama.
FAU - Baggett, Sara
AU  - Baggett S
AD  - McWhorter School of Pharmacy, Samford University.
FAU - Kyle, Jeffrey A
AU  - Kyle JA
AD  - McWhorter School of Pharmacy, Samford University.
FAU - Skelley, Jessica W
AU  - Skelley JW
AD  - McWhorter School of Pharmacy, Samford University.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Aged
MH  - Canagliflozin
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Interactions
MH  - Glucosides/administration & dosage/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/administration & dosage/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - ADE = Adverse drug event
OT  - AE = Adverse effects
OT  - AHA = Antihyperglycemic agent
OT  - AUC = Area under the curve
OT  - BMI = Body mass index
OT  - BP = Blood pressure
OT  - CAN = Canagliflozin
OT  - CKD = Chronic kidney disease
OT  - CV = Cardiovascular
OT  - Canagliflozin
OT  - DBP = Diastolic blood pressure
OT  - Diabetes
OT  - Elderly
OT  - FPG = Fasting plasma glucose
OT  - Geriatrics
OT  - HDL-C = High-density lipoprotein cholesterol
OT  - ITT = Intention-to-treat
OT  - LDL-C = Low-density lipoprotein cholesterol
OT  - SBP = Systolic blood pressure
OT  - SGLT2 = Sodium glucose cotransporter 2
OT  - SGLT2 inhibitor
OT  - SU = Sulfonylurea
OT  - T2DM = Type 2 diabetes mellitus
OT  - Type 2 diabetes
OT  - UGT = UDPglucuronosyl transferase
OT  - UTI = Urinary tract infection
OT  - eGFR = Estimated glomerular filtration rate
EDAT- 2014/05/23 06:00
MHDA- 2015/03/03 06:00
CRDT- 2014/05/23 06:00
PHST- 2014/05/23 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - 1378V3353V36T276 [pii]
AID - 10.4140/TCP.n.2014.335 [doi]
PST - ppublish
SO  - Consult Pharm. 2014;29(5):335-46. doi: 10.4140/TCP.n.2014.335.